Skip to main
ASTH

ASTH Stock Forecast & Price Target

ASTH Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 14%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Astrana Health is expected to experience strong growth in revenue and adjusted EBITDA in the coming years, as shown in their FY26 financial guidance. Despite potential risks from recent acquisitions, the company's integrated platform for value-based contracts and focus on the senior and chronic illness patient population suggests a promising future. However, the company's high debt load may limit their flexibility and strategic options for expansion through acquisitions and partnerships.

Bears say

Astrana Health is facing several risks including execution risk from recent M&A, elevated utilization environment, and the potential for delays in realizing expected synergies. With a forecasted EV/EBITDA multiple of 7.5x FY26 estimate, it is trading at a discount compared to the FFS hospital operator group. However, the company's strong financial model, scalable technology, and partnerships with large payers such as United Healthcare and Aetna provide potential for upside in the long-term. Investors should monitor utilization trends and execution of M&A strategy closely.

ASTH has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Astrana Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Astrana Health Inc (ASTH) Forecast

Analysts have given ASTH a Strong Buy based on their latest research and market trends.

According to 7 analysts, ASTH has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Astrana Health Inc (ASTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.